Simon Amy sold $429K of BEAM
Simon Amy (Chief Medical Officer) sold 16,667 shares of Beam Therapeutics Inc. (BEAM) at $25.74 ($0.43M total) on 2026-07-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale size, price, and 10b5-1 status; it does not include any new clinical, regulatory, or financial guidance.
Market read
Traders may note insider selling, but the 10b5-1 framing suggests limited incremental information for valuation.
What to watch
The article provides only the sale details, not any concurrent buy activity, changes in guidance, or operational updates that would connect the transaction to fundamentals.
Background
This is an SEC Form 4 insider transaction for Beam Therapeutics, reported by the Chief Medical Officer.
Ticker impact
Beam Therapeutics CMO Simon Amy filed a Form 4 showing an open-market sale of 16,667 shares at $25.7417 on 2026-07-27.
Likely minimal immediate price impact; any effect is more about sentiment than new company information.
The disclosure is a Form 4 insider transaction, but it explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification or tax planning and may not reflect negative expectations, especially under a 10b5-1 plan.
Key entities
- issuerBeam Therapeutics Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderSimon Amy
Chief Medical Officer who sold shares under a pre-arranged 10b5-1 plan.
